CTOs on the Move

Trevi Therapeutics

www.trevitherapeutics.com

 
Trevi Therapeutics, Inc. is a late-stage clinical development company developing Nalbuphine® ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic, and neuropathic conditions. The Company is pursuing two conditions for clinical development: uremic pruritus and prurigo nodularis. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with significant impairment in quality of life and increased mortality. Prurigo nodularis is an intensely pruritic dermatologic condition characterized by unsightly and itchy skin papules and nodules. There are no approved therapies in the United States or Europe for either condition.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Trevi Therapeutics raised $50.5M on 07/20/2017
Trevi Therapeutics raised $55M on 04/07/2022

Similar Companies

Immtech Pharmaceuticals

Immtech Pharmaceuticals is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TotalDrugmart.com

TotalDrugmart.com is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Karuna Pharmaceuticals

Karuna Pharmaceuticals is a clinical-stage company targeting muscarinic cholinergic receptors for the treatment of psychosis and cognitive impairment across central nervous system (CNS) disorders.

Mysite

Craft Health is a pharmaceutical drug delivery company that uses 3D printing technology to create personalized medicines and supplements for its customers.

ALDA Pharmaceuticals

ALDA Pharmaceuticals Corp. is a Richmond, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.